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Should adjuvant therapy be used in patients with colorectal cancer 
in pathological stage II?
Rafał Stec
In meta-analyses and reliable randomised clinical trials, the most favourable therapeutic gain of adjuvant therapy 
of patients with colorectal cancer in stage II was estimated at 3% (in the majority of meta-analyses no statistical si-
gnificance was). Considering the side effects, especially the mortality rate in chemotherapy (FOLFOX reached 0.5%, 
and in the case of 5-fluorouracil, the occurrence of toxicity grade 3 and 4, increased the risk of patient death by ap-
proximately 1%) seems to be questionable. Because of the lack confirmation of the effect of systemic treatment, an 
increase of the percentage of cured patients in the second stage has led to the development of several genetic tests 
determining the genetic signature of colorectal cancer. The aim of these tests is to identify the groups of patients 
that could potentially achieve the greatest benefit from adjuvant therapy. The most important tests are: “Oncotype 
DX”, “ColoPrint” and “GeneFx”. However, at the moment, there is no clear scientific evidence in favour of the standard 
use of adjuvant chemotherapy in patients with colon cancer in stage II.
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Currently there is no evidence-based data providing ar-
guments for the application of adjuvant therapy in patients 
with colorectal cancer in pathological stage II. Below there 
are arguments against the use of adjuvant chemotherapy 
in the above clinical situation.
The meta-analysis which points to the lack of benefits 
resulting from such a treatment pattern is, among others, 
the “Intergroup” meta-analysis, comprising 7 clinical studies 
(total number of colorectal cancer patients: 3302), in which 
the adjuvant therapy regimen was based on treatment with 
5-fluorouracil in combination with levamisole or folic acid. 
The rate of patients with a 5-year DFS (disease-free survi-
val) period in the “N0” patient group receiving adjuvant 
therapy in comparison with the group of patients without 
chemotherapy was 76% vs 72% respectively (p = 0.0490), 
whilst there was no improvement with regards to OS (overall 
survival): 81% vs 80% respectively (p = 0.1127) [1].
In the systematic review (altogether 37 clinical studies 
and 11 meta-analyses) published by the “Ontario group”, 
the final analysis concerned 4187 patients with colorectal 
cancer in pathological stage II, who, in the chemotherapy 
arm, received the regimen based on at least 5-fluoroura-
cil in monotherapy. In the group of patients treated with 
chemotherapy, DFS improved by 5–10%, which did not 
translate to a significant improvement of OS (HR = 0.87, 
95% CI, 0.75–1.10; p = 0.07) [2, 3]. 
Likewise, no statistically significant benefit was observed 
in the “Impact B2” meta-analysis (5 clinical trials, 1016 pa-
tients: T3N0) with regards to the improvement of the DFS in 
patients treated with chemotherapy (regimen 5-fluorouracil 
and folinic acid) in comparison with patients undergoing 
observation alone (76% vs 73% respectively) and a 5-year 
OS (82% vs 80% respectively) [3, 4]. 
A slight benefit in the use of adjuvant chemotherapy was 
observed only in the “QUASAR” clinical study (“QUick And 
Simple And Reliable”). The study comprised 3238 subjects 
with colorectal cancer with so-called “uncertain indications 
for adjuvant therapy” (only 2146 subjects had pathological 
stage II of colorectal cancer): 71% had a diagnosis of colon 
cancer and 29% of rectal cancer. The chemotherapy con-
sisted of a three or two-drug regimen: 5-fluorouracil with 
folinic acid with or without the addition of levamisole. The 
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improvement in the 5-year OS was obtained in the group 
with chemotherapy in comparison with the patients un-
der observation alone (83.9% vs 81.5%; HR = 0.86, 95% CI, 
0.54–1.19). [3, 5].
The presented analyses included in total more than 10 
600 patients with pathological stage II colorectal cancer 
obtaining uncertain benefit only in one clinical study (the 
patients enrolled had colorectal cancer and various che-
motherapy schemes were applied) at the level of about 3%.
These conclusions may also be confirmed by the results 
of a retrospective analysis which included the “SEER-Medica-
re” (“Surveillance, Epidemiology, and End Results”) database 
from 1992–2005 comprising as many as 24 847 patients with 
pathological stage II colorectal cancer. 75% of patients had 
at least one or more negative prognostic factors (hospital 
admission on an emergency basis on account of colorectal 
cancer, intestinal perforation, ileus, tumour size T3 or T4, 
poor differentiation of the tumour, the number of lymph 
nodes in the specimen < 12), and, in this group, 20% of 
subjects received adjuvant chemotherapy. No statistically 
significant differences were found between the two gro-
ups of patients: without negative prognostic factors and 
untreated with chemotherapy (the 5-year OS was 70.0% 
vs 69.5% respectively; [HR = 1.02; 95% CI; 0.84–1.25]) and 
also with at least one or more negative prognostic factors, 
treated and untreated with chemotherapy (5-year OS was 
56.7% vs 56.1% respectively; [HR = 1.03; 95% CI, 0.94–1.13). 
A significant benefit in the adjuvant treatment was obtained 
solely by patients with pathological stage III (HR = 0.64; 95% 
CI, 0.60–0.67) [6]. 
The largest published database of patients with pa-
thological stage II colorectal cancer (“National Cancer Data 
Base”), which finally included the cohort of 153,110 pa-
tients, evaluated the influence of adjuvant chemotherapy 
on the 5-year OS, among others in the group of “high” and 
“low” risk patients. A significant improvement in OS was 
related to the use of adjuvant chemotherapy in all patient 
subgroups irrespective of the presence of histopathologi-
cal risk factors (poorly or non-differentiated tumour, pT4 
tumour, positive surgical margin, < 12 lymph nodes in the 
post-operative histopathological specimen), patient age, 
chemotherapy regimen or even after the correction of the 
results with regards to independent variables (HR = 0.76, 
p < 0.001). Although the authors proved the benefits in 
post-operative chemotherapy, the presented analysis has 
some significant limitations, which clearly undermine the 
obtained results. The reduction of the value of the study is 
related to its retrospective and unplanned character, lack of 
random selection of the patients and the resulting lack of 
balance between specific patient groups (large, significant 
disproportion between specific patient groups: the gro-
ups of patients without chemotherapy was 4 times larger), 
non-stringent procedures concerning the collection of cli-
nical data concerning the subjects, doubts concerning the 
improvement of OS after adjuvant chemotherapy in the 
“low-risk” patient subgroup, diverse follow-up periods (the 
enrolment scope was 1998–2011 without the presentation 
of the data concerning the median period and the scopes 
of the follow-up period) [7].
Some more published data concerning the efficacy of 
adjuvant chemotherapy applied to patients with pathologi-
cal stage II colorectal cancer are taken from a Dutch register 
(The Netherlands Cancer Registry) covering the period from 
2008–2012. The analysis comprised 10,935 patients, inclu-
ding 4940 (45%) with the presence of risk factors (poorly or 
non-differentiated tumour, pT4 tumour, emergency surgery, 
and or < 10 lymph nodes in the post-operative histopatholo-
gical specimen) out of which adjuvant therapy was received 
by 790 patients (16%). A significant improvement in the 
3-year OS was obtained only in the groups of patients with 
pT4 cancer, who received chemotherapy in comparison with 
the group of patients under observation only (91% vs 73%, 
HR = 0.43, 95% CI 0.28–0.66) [8]. The results of the Dutch 
registry do not differ significantly from those presented in 
the “National Cancer Data Base” or in “SEER-Medicare”, which 
definitely undermines the credibility of such analyses.
 Also no efficacy improvement was obtained in the case 
of chemotherapy applied in pathological stage II of colo-
rectal cancer consisting of the addition of oxaliplatin to 
the two-drug regimen (5-fluorouracil and folinic acid). In 
the “MOSAIC” clinical study in which about 40% of subjects 
had pathological stage II colorectal cancer (899 patients), 
the 10-year OS was, in the case of the group treated with 
chemotherapy with oxaliplatin added (FOLFOX 4) 78.4% vs 
79.5% for the group treated solely with 5-fluorouracil and 
folinic acid, yet without obtaining statistical significance 
(HR = 1.004, 95% CI 0.744–1.354; p = 0.981). Similarly, no 
significant improvement of the OS was observed either in 
the “high risk” group with pathological stage II colorectal 
cancer (HR = 0.895; 95% CI, 0.606–1.323; p = 0.578), or in 
the “low risk” subgroup (HR = 1.168; 95% CI, 0.730–1.870, 
p = 0.515) [9].
It was not clearly determined whether the patients 
from the “high risk” group should receive chemotherapy 
in a situation when the post-operative histopathological 
assessment reveals one, two or a few adverse prognostic 
factors, which proves the lack of consistency among the 
recommendations of international committees and societies 
with regards to the use of chemotherapy in pathological 
stage II of colorectal cancer, and undoubtedly illustrates how 
controversial this treatment is [3]. The most significant fac-
tors influencing treatment decisions are presented in Table I.
With regards to the lack of any reliable confirmation on 
the influence of post-operative systemic treatment on the 
increase in the rate of cured patients with pathological stage 
II of colorectal cancer, a number of genetic tests have been 
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worked out which specify the gene signature of colorectal 
cancer. The purpose of these tests is the identification of 
the group of patients who could potentially benefit most 
from such treatment. The most important tests are: “On-
cotype DX” (12-genes), “ColoPrint” (18-gene) and “GeneFx” 
(482-genes) [3]. 
Currently the test “Oncotype DX”, which was worked 
out and validated on the basis of a few studies, such as 
“OUASAR”, “CALGB 9581” (“Cancer and Leukemia Group B”) 
and “NSABP C-07” (“National Surgical Adjuvant Breast and 
Bowel Project C-07”) is the most widely used. On the basis of 
the analysis of the dependence of the correlation of genes 
and the recurrence score (RS), some algorithms have been 
specified with a purpose to assess the risk of recurrence of 
colorectal cancer and the benefits from the use of adjuvant 
chemotherapy. On the basis of these algorithms (based on 
the analysis of the patients from the “QUASAR” study treated 
only with surgery), the patients belonging to specific groups 
may be identified: low risk of recurrence (3-year recurrence 
risk is 12%), moderate risk (3-year recurrence risk is 18%), 
high risk (3-year recurrence risk is 22%). In an independent 
clinical “validation” study (patients from the “NSABP C-07” 
study) the mean 5-year risk of disease recurrence, after the 
application of adjuvant chemotherapy containing 5-flu-
orouracil, was, respectively: 9% in low risk groups (95% CI, 
6–13%), 13% in medium risk groups (95% CI, 8–17%) and 
18% in high risk groups (95% CI, 12–25%). The benefits in 
Table I. Indications for adjuvant chemotherapy in patients with pathological stage II of colorectal cancer according to various scientific committees 
and societies
The name of a scientific committee or a society ASCO NCCN ASCRS NCI ESMO JSCCR NHMRC
General remark: “for patients with a high risk of disease 
recurrence”.
X X
Too small number of lymph nodes in the histopathological 
specimen 
X X X X
< 12 lymph nodes in the histopathological specimen X X
Tumour pT4 X X X X X
Tumour perforation X X X X X
Ileus X X X
Poorly or non-differentiated tumour: G3, G4 X X X X X X
Lymphatic vessels involvement X X X
Blood vessels involvement X X X
Perineural invasion X X X
Positive surgical margin X
Comorbidities X
Estimation of predicted survival X
Molecular tests concerning DNA disorders of the cancer X
The possibility of participation in a clinical study X
Obtaining informed consent for the treatment X
ASCO (American Society of Clinical Oncology [in collaboration with the Cancer Care Ontario Practice Guideline Initiative]), ASCRS (American Society of Colon and Rectal 
Surgeons), ESMO (European Society for Medical Oncology), JSCCR (Japanese Society for Cancer of the Colon and Rectum), NCCN (National Comprehensive Cancer 
Network), NCI (National Cancer Institute), NHMRC (Cancer Council Australia/Australian Cancer Network. National Health and Medical Research Council)
the application of adjuvant therapy with regards to the 
3-year risk of recurrence, as specified on the basis of the 
“OUASAR” study, after a 5-year treatment period were 3%, 
5% and 4% respectively. An important drawback of this test 
is the price: 3280 USD, which makes its wide use in clinical 
practice impossible, as well as the lack of prospective eva-
luation of the influence of chemotherapy on the reduction 
of the risk of recurrence and the improvement of overall 
survival [3, 10–12]. 
Another test applied for the identification of patients 
in specific risk groups is “ColoPrint”. On the basis of a non-
-randomised, cohort “validation” study (114 samples), two 
risk groups were specified: a low risk group, in which a 5-year 
relapse-free survival (RFS) and 5-year metastasis free survi-
val period (MFS) concerned 87.6% and 94.9% of patients 
respectively and the high risk group in which the 5-year 
RFS and 5-year MFS concerned 67.2% and 80.6% of patients 
respectively. In spite of promising results, the “ColoPrint” 
test has also a number of significant drawbacks. Apart from 
the high cost of its application, some doubt is raised by the 
small number of patients included in the “validation” study 
with varied pathological stages — from I to III, the necessity 
of obtaining fresh-frozen tumour tissues for molecular ana-
lyses, the lack of prospective evaluation of the influence of 
chemotherapy on the reduction of RFS and MFS risks or on 
the improvement of overall survival in specific study groups 
and the possibility of distortion of the results by means of 
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including a significant number of tumours with the BRAF or 
MSI gene mutation into the study [3, 13, 14].
Another test which may potentially be used for the 
identification of recurrence risk in patients with pathological 
stage II of colorectal cancer is a “GeneFx”, a multi-gene test, 
on the basis of which (the analysis of the paraffin-embedded 
samples and clinical data obtained from 144 patients from 
12 centres) the 5-year recurrence risk and 5-year OS were 
evaluated in the validation study. This allowed for distingu-
ishing between groups with a low and high risk of disease 
recurrence. In the low-risk group, the 5-year recurrence 
risk was 30%, and the rate of 5-year survival was — 75% of 
patients, whilst in the high risk group it was 55% and 60% 
respectively. The patients in the high risk group of disease 
recurrence in comparison with patients in the low risk group, 
had a two and a half-fold higher risk of disease recurrence 
(HR = 2,53; p < 0,001). The results were again evaluated 
on the basis of histopathological material concerning 393 
patients who were treated within the “CALGB 9581” clinical 
study. 177 patients (45%) were categorised as patients with 
a low risk of recurrence and 216 (55%) as patients with a 
high risk of recurrence. The risk of disease recurrence in the 
group of patients classified as a group with the high risk of 
recurrence, (in comparison with the patients from the group 
with a low risk of recurrence) was statistically significant, 
as it was twice as high (HR = 2.13; 95% CI, 1.3–3.5), whilst 
the 5-year disease-free interval was 82% versus 91% in the 
specific groups respectively. 
A disadvantage of this test, similarly to the case of the 
previously described ones, is the high cost and the lack of 
a prospective evaluation of the influence of chemotherapy 
on the reduction of the risk of disease recurrence and the 
improvement of overall survival [3, 15, 16]. The genetic tests 
are summarised in Table II.
Another important aspect which determines the treat-
ment possibilities, apart from efficiency, is toxicity. In the 
case of adjuvant chemotherapy, in patients with colorectal 
cancer, the pathological stage of the disease is connected 
with a significant increase (from 15% to even 53%) in the 
risk of adverse reactions in the GI tract (nausea, vomiting, 
alimentary tract mucositis, diarrhoea), a risk of leukopenia 
(from 8% to 30%) or a neuropathy risk, which may concern 
even as many as 84% of patients treated with oxaliplatin, 
which definitely leads to a deterioration in the quality of 
life. Nevertheless, the most important complication of che-
motherapy is the patient’s death. In the group of patients 
treated with the FOLFOX regimen, the mortality rate was 
0.5%, whereas in the case of 5-fluorouracil, third and fourth 
degree toxicity increased the risk of a patient’s death by 
about 1%. Moreover, adjuvant treatment requires frequent 
patient visits to hospital, in chemotherapy wards (either 
on an outpatient or inpatient basis) for a period from 6 to 8 
months, which directly affects the family, social and profes-
sional life of patients [3, 17–20]. The costs of chemotherapy 
must not be forgotten either, for example in the “QUASAR” 
study, it was estimated that this costs ranged from 2000 GBP 
Table II. The available genetic tests used for the evaluation of the prognoses of colorectal cancer patients
Test name Oncotype Dx ColoPrint GeneFx
The number of examined 
genes
12 18 482
“validation” studies “QUASAR” “NSABP C-07” A study on an independent 
patient cohort. Prospective 
analysis of risk stratification 
(PARSC)
A study on an independent patient cohort, 
“CALGB 9581” 
Results 3-year recurrence risk “QUASAR”: 
– the group of low risk of 
recurrence: 12%
– the group of medium risk of 
recurrence: 18%
– the group of high risk of 
recurrence: 22%
“Validation” study (“NSABP C-07 ”) 
after the application of adjuvant 
chemotherapy containing 
5-fluorouracil, the mean risk of 
recurrence in the specific groups 
was:
– low risk: 9% (95% CI, 6–13%)
– medium risk: 13% (95% CI, 
8%–17%)
– high risk: 18% (95% CI, 12–
25%)
5-year relapse free survival 
(RFS): 
– low risk: 87.6%
– high risk: 67.2%
5-year metastases free 
survival (MFS):
– low risk: 94.9%
– high risk: 80.6%
An independent cohort: 
 5-year risk of recurrence: – low risk group: 30%, 
– high risk group: 55%
The group of high risk of disease recurrence 
in comparison with the group of low risk of 
recurrence had a two and half-fold higher risk of 
disease recurrence, HR = 2.53; p<0,001)
5-year OS: 
– low risk group: 75%
– high risk group: 60%
 “CALGB 9581” 393 patients: 177 patients (45%) 
a low disease recurrence risk group, 216 patients 
(55%) a high disease recurrence risk group; the 
high disease recurrence risk group in comparison 
with the low risk group had a twofold higher risk 
of disease recurrence (HR = 2.13; 95% CI, 1.3–3.5); 
the 5-year recurrence-free interval was, in specific 
groups: 82% vs 91% relatively
RFS (relapse-free survival), MFS (metastasis-free survival), OS ( overall survival)
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to 3000 GBP per patient [3, 5]. The social costs or the costs 
of the lack of professional activity of the patients during 
systemic post-operative therapy were not assessed.
To sum up, currently there is no reliable evidence which 
might definitely argue for the use of adjuvant chemotherapy 
in colorectal cancer patients with pathological stage II of 
the disease. The majority of scientific data argue against 
such treatment patterns, as it causes only adverse effects 
without any significant improvement in survival indicators. 
Reply
Some adverse prognostic factors qualifying patients 
to the “high risk” group are not related to tumour biology, 
but only with suboptimal surgery. These factors comprise: 
the number of resected lymph nodes below 12, as well as 
positive or not adequate surgical margins (e.g. R1 resection). 
Therefor it seems more important to maintain standards 
in surgical treatment than to use adjuvant chemothera-
py. Some reliable studies with randomisation and meta-
-analyses show that the most optimistic therapeutic gain 
(improvement of 5-year survival) from adjuvant treatment 
in patients with pathological stage II colorectal cancer was 
established to be 3% (in the majority of meta-analyses no 
statistical significance was gained). Yet, given the adverse 
effects, and, in particular, the mortality rate with the chemo-
therapy used (with the FOLFOX regimen it was 0.5%, and in 
the case of 5-fluorouracil with the third and fourth toxicity 
grade it increased the mortality risk by about 1%), such 
treatment patterns seems to be highly doubtful. 
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